drugset
drugset / Trial / NCT06895031

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT06895031 ↗

Phase 2 Recruiting 210 enrolled Guangzhou JOYO Pharma Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.

Timeline

Start
2025-03-31
Primary completion
2026-03-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JYP0015 Unknown — Oral

Indications

colorectal cancer non-small cell lung carcinoma pancreatic ductal adenocarcinoma